Nanoparticle Mediated Gene Therapy Diabetic Retinopathy Biology Essay

A. Specific AIMS: Diabetic retinopathy ( DR ) , brought on as a consequence of complications attributed to diabetes, is the taking cause of preventable sightlessness among grownups aged 20-74 old ages in the industrialised universe. Approximately half of all patients with diabetes will, at one clip or another, have some grade of retinopathy and with the prevalence of diabetes expected to lift steadily in the foreseeable hereafter DR will go on to attest as a important complication in patients with diabetes. Although pan-retinal photocoagulation ( PRP ) continues to be the standard intervention for DR, its clinical restrictions and inauspicious effects have led to an geographic expedition of alternate schemes for intervention [ x-Jardeleza ] . One keeping great promise is cistron therapy using fresh DNA nanoparticles ( NPs ) . For some clip optic cistron therapy utilizing viral vectors have shown limited success ( e.g. , AAV2 stage I clinical tests for Leber Congenital Ameroses ( LCA ) ) , with noteworthy restrictions which include size of look cassette delivered, cellular tropism, and issues of safety. Along with others we have successfully created and used fresh self-compacted Deoxyribonucleic acid nanoparticles capable of efficient durable look within 1 hr of disposal. The engineering used to build these DNA nanoparticles is able to pack a DNA vector of up to 20 kilobits in size into a nanoparticle holding a concluding diameter of merely 8 nanometers. Our ain proof-of-principle surveies have demonstrated that these NPs are safe, effectual, non-toxic and efficient as non-viral cistron transportation machinery for usage in the retina [ 4-11 ] . The clinical viability for the usage NPs as a curative scheme in the intervention of DR is favourable given informations back uping its efficaciousness with other signifiers of retinal disease [ x ] . In this grant application, we plan to use our optimized NP-mediated cistron transportation scheme, entirely or combined with siRNA aiming system, for the intervention of DR. The Deoxyribonucleic acid NPs will be delivered intravitreally into the Ins2Akita, an established mouse theoretical account for the survey of the molecular footing involved in the early patterned advance of DR [ x-2005 Barber ] . The Ins2Akita mice were inherited as an autosomal dominant, which resulted in a individual amino acerb permutation in the insulin 2 cistron that causes misfolding of the insulin protein [ 12 ] . Heterozygous males for this mutant have important hyperglycaemia, hypoinsulinemia, and early marks of DR that made it as an first-class type 1 diabetic mouse theoretical account for analyzing DR [ 12, 13 ] . Since the high degrees of VEGF and PEDF are present in vitreous fluid and inhibitors of angiogenesis are by and large abundant in the vitreous fluid [ 14, 15 ] , we will shoot the carnal intravitreally. Our immediate end is to develop a safe and an efficient non-viral remedy to battle ocular loss in a theoretical account of DR.

Aim 1. Anti-VEGF targeting in Ins2Akita mice of DR utilizing NP vectors. We will buy four pre-defined little interfering RNAs ( siRNAs ) , ( Dharmacon, Inc. ) that mark sequences within the VEGF chief receptors on the endothelial cell plasma membrane following NP-mediated debut into the oculus. The short hairpin RNA ( shRNA ) look vectors driven by the RNA polymerase III H1 booster will be cloned foremost, and their efficiency and specificity will be tested prior to NP building and intravitreal bringing to the diabetic mouse theoretical account of DR.

Aim 2. Evaluation of optimum NP-mediated PEDF cistron transportation into optic cells following intravitreal injection in a diabetic mouse theoretical account of DR. The ultimate intervention for vision-threatening DR may necessitate multiple modes. In this purpose, NPs transporting the PEDF cistron of involvement driven by strong cosmopolitan CBA and/or CMV early enhancer/chicken I?-actin ( CAG ) boosters will be injected into the intravitreal infinite of Ins2Akita males at postpartum ( P ) twenty-four hours 60 before the oncoming of DR. Outcome measurings of map will be obtained by electroretinography ( ERG ) and psychophysical vision proving by OptoMotry ; measurings of construction will be obtained by histological analysis of retinal vas formation at the visible radiation and EM degrees and by immunohistochemistry ( IHC ) ; and measurings of biochemical activity will be obtained by qRT-PCR and quantitative Western blotting analysis to measure PEDF look in order to assay multiple facets of the disease procedure.

B. BACKGROUND AND SIGNIFICANCE: Diabetic retinopathy ( DR ) is a important ocular complication of diabetes and is the taking cause of sightlessness among working-aged grownups. Globally, the incidence of diabetes is expected to lift steadily as a effect of lifestyle properties that lead to fleshiness. The quality of life of patients is badly affected by the partial or complete loss of vision, hence there is a great demand for developing fresh therapeutics that are safe and effectual for forestalling and handling DR.

( 1 ) Model of DR: The Ins2Akita mouse, foremost identified in 1997 [ 12 ] , is an autosomal dominant mutant diabetic type 1 theoretical account without insulitis or fleshiness [ 12 ] and has been the most extensively studied theoretical account of this sort [ 12, 13, 16-18 ] . These non-obese mice were noted to be hyperglycemic and hypoinsulinemic by 4-6 hebdomads of age [ 12 ] and develop diabetic complications including early oncoming of DR [ 13 ] , neuropathy [ 19 ] , and nephropathy [ 18 ] . The Ins2Akita mouse encodes for a individual base brace permutation at the insulin 2 cistron on chromosome 7 in a C57BL6 mouse background ensuing in replacing of cysteine with tyrosine at place 96 ( C96Y ) and is transmitted as an autosomal dominant trait. The permutation disrupts the bulk of go arounding insulin in the C57BL/6 wild type because of improper folding of the insulin 2 protein, ensuing in badly hyperglycemic and hypoinsulinemic syndrome. The phenotype of the syndrome is more marked in Akita male than in the female. The Ins2Akita mouse has an advantage over other mouse strains for the probe of DR because: ( I ) it ‘s a really common familial diabetic mouse theoretical account ; ( two ) it shows early age of diabetes onset ( 4-6 hebdomads ) [ 12, 13 ] and early marks of DR ( 12 hebdomads ) [ 13 ] when compared with others theoretical accounts, such as diabetic type II db/db mouse ( early marks of DR ~20 hebdomads ) [ 20 ] ; ( three ) it is known to bring forth intraocular neovascularization which mimics the vascular proliferative stage of DR ; ( four ) it is easy bred and fertilized ; ( V ) its diabetic position mimics human insulin-dependent diabetes mellitus ( IDDM ) which can be maintained in a province without exogenic insulin [ 13 ] ; and ( six ) the DR manifested is more common in those with type I diabetes [ 21 ] . Therefore, it is a suited theoretical account for proving NP-mediated non-viral intervention hypotheses for DR.

( 2 ) The function of VEGF in DR: To forestall the oncoming or patterned advance of DR, cardinal factors involved in both the vascular and neural abnormalcies which lead to DR must be addressed. VEGF is a critical constituent in the tissue growing and organ fix procedures of angiogenesis and vasculogenesis. It is critical for advancing the formation of collateral vass after ischaemic events and plays a cardinal function in lesion healing. However, this really map of VEGF besides plays a cardinal function in the development of both proliferative DR and diabetic macular hydrops. In diabetic rats, VEGF was overexpressed in diabetic retinas, bespeaking that VEGF seems to play an of import function in the dislocation of the blood-retinal barrier in simple DR. In recent old ages, the usage of anti-VEGF agents has emerged as a new attack to the intervention of these lay waste toing diabetic complications. Inhibition of VEGF can forestall the diabetes-induced permeableness, bespeaking a direct function for VEGF in this pathology. Intraocular bringing of anti-VEGF therapies is now widely used to handle AMD, and clinical tests for intervention of DR are presently being evaluated. All members of the VEGF household stimulate cellular responses by adhering to cell surface tyrosine kinase receptors ( the VEGFRs ) . VEGF receptor-1 ( VEGFR-1 ) , besides known as Flt-1 ( fms-like tyrosine kinase receptor-1 ) , is found chiefly in endothelial cells and are indispensable for vasculogenesis and vascular care. VEGF receptor-2 ( VEGFR-2 ) , besides known as the kinase sphere part ( KDR ) , is found chiefly in endothelial and haematopoietic cells and their precursors. VEGFR-2 mediates about all endothelial cell responses to VEGF and is of import for vascular and haematopoietic development. VEGFR-3 ( fit-4 ) is restricted chiefly to the grownup lymphatic endothelium. VEGFR-3 preferentially binds to VEGF-C and VEGF-D and may be involved in the control of lymphangiogenesis. VEGF and its receptors are good marks for curative intercession of DR because VEGF receptors are extremely specific and are expressed in increased Numberss during pathological vascular growing. Down-regulation of VEGF inhibits retinal angiogenesis when exogenously administered. Therefore, our program is to downregulate the look of VEGF via specifically designed RNAi.

( 3 ) The function of PEDF in DR: PEDF, on the other manus, acts as an anti-angiogenic factor in the retina by suppressing the migration of endothelial cells [ 22 ] . PEDF is a 50-kDa protein that is endogenously expressed in optic tissues and other neural and non-neuronal tissues. It has neural differentiating and endurance activities and behaves as an inhibitor of angiogenesis ; The PEDF cistron portions structural and sequence homology with members of the serpin cistron household [ 23 ] . Yet, unlike many serpins, PEDF does non suppress serine peptidases [ 24 ] . Alternatively, it exhibits powerful antiangiogenic, neurotrophic and neuroprotective activities. Numerous surveies support the function of PEDF in neural development, distinction, and survival [ 25-27 ] . More late, PEDF has been demonstrated to be a major constituent of the optic vitreous and aqueous wit where it has been implicated as a powerful inhibitor of angiogenesis [ 22 ] . Therefore, PEDF is best campaigner for bar the increased vascular permeableness and to barricade the neural cell decease in DR disease. The 2nd option we plan to take is to over-express PEDF in the DR theoretical account to suppress DR-associated angiogenesis. Surveies besides show that VEGF and PEDF behave in a reconciliation manner and the ratio of VEGF/PEDF corresponds with retinal neovascularization [ 28 ] . Sing these considerations, a combination of transgenes that act on different facets of angiogenesis may increase the efficaciousness of cistron therapy for DR bar.

( 4 ) The functions of CBA/CAG booster: Main surveies of DR have been focused on retinopathy associated with the vascular web known as microangiopathy, which is characterized by harm to endothelial cells run alonging retinal blood vass and pericytes. Retinal neovascularization in DR occurs off from the RPE and toward the vitreous infinite. In our experimental program, we propose to utilize the CBA and/or CAG universal boosters that are known to heighten vector look without bring oning humoral and cellular immune responses [ 29, 30 ] ( such as the conventional CMV does ) to drive curative cistrons in the vitreal infinite of DR mouse theoretical account ( please besides see our preliminary informations, Fig. 1 ) .

( 5 ) Gene therapy for optic diseases: Ocular diseases can be by and large divided into three classs which are: 1 ) eyepiece upsets that are a known to be caused by a specific type of familial mutant ; 2 ) eyepiece diseases where the specific familial constituent is unknown or ill-defined ; and 3 ) eyepiece diseases that are non genetically based. To day of the month, over 150 retinal disease-causing cistrons have been identified. Disorders in the first two classs cause a big assortment of enfeebling retinal devolutions for which there are no healing interventions. Gene therapy in oculus can be merely split into two classs, cistron replacing and cistron ordinance ( such as a grade to which a cistron is knockdown, turned on or off ) . Gene therapy needs a vector to present the curative cistron to the mark cells. The most challenge facing cistron therapy is to present quantitatively precise look of cistrons in the right cell type and at the right clip without host unsusceptibility caused. Therefore far, bringing methods can be loosely divided into viral and non-viral attacks. Historically, viral vectors have been the most efficient ( in footings of cell bringing ) and the most popular bringing pick in optic cistron therapy, but they can be limited by cell tropism, size of the look cassette to be transferred, and host unsusceptibility to repeated infections. Recent progresss in the preparation of non-viral vectors have greatly improved their efficiency and non-viral cistron therapy research has been turning in popularity.

( 6 ) Ocular nano-gene therapy: A NP is defined as any molecular atom that is less than 100 nanometres in size and behaves as a whole unit in footings of its conveyance and belongingss. Nanotechnology is a multidisciplinary interactions between the interdisciplinary convergence of basic Fieldss ( such as chemical science, natural philosophies, mathematics and biological science ) and applied Fieldss ( such as stuffs scientific discipline and the assorted countries of technology ) , which contributes to the functional results of the engineering. Although multiple different types of NPs have been used to present curative cistrons, a presently popular and successful preparation involves the compression of a individual molecule of plasmid DNA with a PEG substituted lysine 30-mer [ 8, 10, 31, 32 ] . The ensuing atoms have a really little size ( 8-20nm in diameter ) and are either rod or ellipsoidal in form ( depending on the counterion nowadays at the clip of compression ) .This engineering can be used to pack any type of nucleic acid, linear or round, individual or dual stranded. Self-compacted DNA NPs as a system for non-viral cistron transportation have no theoretical restriction on plasmid size and have been tested with plasmids up to 20kb, do non arouse an immune response in the systems tested ( lung and oculus ) , and can be extremely concentrated [ 6-8 ] . The compacted atom is expeditiously taken up into spliting and non-dividing cells and remains episomal. These NPs have been shown to be safe and effectual in a human clinical test for cystic fibrosis and are presently being employed in multiple different organ systems [ 8, 10, 31-34 ] .The efficiency of CK30PEG-compacted DNA NPs as a system for non-viral cistron transportation to optic tissues have shown no theoretical restriction on plasmid size, do non arouse immune response, and can be extremely concentrated [ 4-8, 11, 32, 35 ] .

Significance: The loss of one ‘s vision is indisputably straitening. DR, which is caused by diabetes, is regarded as “ the soundless slayer of oculus ” . Because of the comparative mild early symptoms and the imperfect, irreversible pathological developing procedure, most patients can hold long clip diabetes before they are diagnosed. However, the conventional intervention is limited. The cost for the patient and the society are burden. The impact on patient ‘s quality of life is important. To research the next-generation of therapeutics for DR is basically needed. Recently, cistron therapy for diabetes and its complications are distributing out on every corner. Given the dangers inherent in the usage of viral vectors, our scheme will enable us to entree the favourable facets of viral vectors while supplying the safety and pharmaceutical qualities built-in in non-viral cistron bringing systems. In a long tally, patients will accept merely non-viral vectors as the ways of intervention. In this survey, we will bring forth schemes concentrate on microvascular and neuropathy to barricade the vascular and neural complications associated with the development and patterned advance in a DR mouse theoretical account through non-viral NP bringing. This will be an of import measure for generate a clinical relevant curative scheme for intervention and bar of the oncoming of DR. Therefore, the result of this application will lend significantly to the future application of cistron therapy for optic upsets in general and DR in peculiar.

C. PRELIMINARY STUDIES: To find the public-service corporation look of CK30PEG NP in optic cistron therapy, we conducted a set of experiments utilizing nanocompacted Deoxyribonucleic acid to show eGFP driven by the mouse rod opsin booster ( MOP 500 ) and a omnipresent CBA booster. Balb/c mice were injected subretinally on P30 and the retinas were cyosectioned at post-injection ( PI ) 15 yearss. Analysis of eGFP fluorescence demonstrated that significant look of eGFP was detected in all beds of the retina after injection with nano-CBA-eGFP, whereas, nano-MOP-eGFP generated transgene look merely in photoreceptor cells.

Fig. 1 In vivo testing of nano-MOP-eGFP and nano-CBA-eGFP. Compacted Deoxyribonucleic acid in H2O ( 4Aµg, 1 Aµl ) was subretinally injected into the eyes of grownup Balb/c mice. ( A ) nano-CBA-eGFP, ( B ) nano-MOP-eGFP, ( C ) Saline injected control. At PI-15 the retinas were cyosectioned and native eGFP look was examined by confocal fluorescence microscopy. OS: Outer Segment ; ONL: Outer Nuclear Layer ; INL: Inner Nuclear Layer ; GCL: Ganglion Cell Layer. Scale saloon: 10 Aµm.

D. EXPERIMENTAL DESIGN AND METHODS:

Aim 1. Four pre-defined siRNAs will be constructed as shRNA driven by the H1 RNA booster and cloned into our late developed mammalian look vector. The most efficient vector will be compacted into NPs and delivered into the vitreal infinite of DR mice. A control vector will be designed to house the inactive shRNA sequence directed by the H1 booster every bit good. Following injection, the degrees of VEGF messenger RNA will be quantified utilizing RNase protection checks and protein degrees will be measured utilizing Western smudge analysis.

Aim 2. In this subdivision, we will 1 ) generate compacted PEG-NP-eGFP and PEG-NP-PEDF under control of CBA and/or CAG boosters and 2 ) evaluate eGFP and PEDF look and localisation following intravetreal at PI-7, PI-30 and PI-90. Rescue will be assessed structurally, functionally, and biochemically. We anticipate these experiments will bring forth functional and structural recovery in DR mice theoretical account. Therefore, the possible scientific and clinical benefits of these proof-of-principles experiments are significant.

Timetable for completion of the grant: Give our experience with surgical processs, anatomical methods, and molecular biological science, it is anticipated that informations garnering for this undertaking will be completed within one twelvemonth. We do non expect any jobs with these two parts of the particular aims since the rule research worker ( PI ) is really familiar with proposed methods and has a significant publication record in the field of cistron therapy. The surveies proposed in this application will lend significantly to the future application of NP cistron therapy for optic diseases. Pending the successful presentation of effectual non-viral NP-mediated initiation in optic cells in mice, and completion of extra toxicology surveies along with our group ‘s old survey on NP-gene therapy for optic upsets, we plan to utilize these informations from the Dr. William “ Bill ” W. Talley II Research Award to use for a R01 grant of NP-mediated cistron therapy with DR diseases.

E. PROPOSAL AS IT RELATES TO HHODC GOALS AND DIABETES RESEARCH: The proposed grant application fits good with ends of Harold Hamm Oklahoma Diabetes Center ( HHODC ) ; the consequences acquired from this work will assist forestall the development of diabetes and its complications in those at hazard, peculiarly in Oklahoma, the most badly affected province in America. This facet is really of import in parts concerned with cistron therapy for familial eyepiece upsets, particularly the on the job category people. Knowledge gained from these surveies will happen direct application in the DR with diabetes. The final payments are both theoretical and applied. At the theoretical degree we are working toward a better apprehension of the pertinence of bio-science theoretical accounts to human populations. On the applied degree our consequences from the proposed application will straight impact quality of life and could be of possible benefit for handling human DR with diabetes by supplying the new high engineering options.

F. PROPOSAL AS IT RELATES TO CAREER GOALS FOR PI: Pi has been active in research for the past 14 old ages, climaxing in a really alone combination of cognition and experience. He foremost worked as a medical physician specialising in neurology. He subsequently expanded his professional involvements to include biomedical research, gaining his Phd in Neurology in 2002 and since that clip has worked on AAV for cistron therapy for neurological and familial mitochondrial upsets. During his post-doctoral preparation, he worked on developing and using safe and effectual cistron bringing schemes for familial and metabolic upsets affecting pre-clinical experiments of cistron therapy through AAV vectors, every bit good as with the human parvovirus vectors. After completing his post-doctoral preparation at the University of Florida, he joined the University of Oklahoma Health Sciences Center ( OUHSC ) as a junior module member in the Department of Cell Biology to prosecute the research work in cistron therapy for neuro-visual diseases utilizing both non-viral nanoparticles and AAV vectors. He has received first manus preparation in vision research since he joined OUHSC. PI has been active in research for the past 14 old ages. He has been extremely productive as shown by the record of his publications. All the needful resources for the PI to continue with his proposed research are available at OUHSC and within the Department of Cell Biology. Funding secured from Dr. William “ Bill ” W. Talley II Research Award would be a important stepping rock for PI as he works towards his end of going a successful independent research worker and a taking expert in familial ocular diabetic research.

1. Maguire, A.M. , et al. , Safety and efficaciousness of cistron transportation for Leber ‘s inborn amaurosis. N Engl J Med, 2008. 358 ( 21 ) : p. 2240-8.

2. Bainbridge, J.W. , et al. , Effect of cistron therapy on ocular map in Leber ‘s inborn amaurosis. N Engl J Med, 2008. 358 ( 21 ) : p. 2231-9.

3. Cideciyan, A.V. , et al. , Human cistron therapy for RPE65 isomerase lack activates the retinoid rhythm of vision but with slow rod dynamicss. Proc Natl Acad Sci U S A, 2008. 105 ( 39 ) : p. 15112-7.

4. Cai, X. , et al. , Gene bringing to mitotic and postmitotic photoreceptors via compacted DNA nanoparticles consequences in improved phenotype in a mouse theoretical account of retinitis pigmentosa. Faseb J, 2009.

5. Ding, X.Q. , et al. , Ocular bringing of compacted DNA-nanoparticles does non arouse toxicity in the mouse retina. PLoS One, 2009. 4 ( 10 ) : p. e7410.

6. Conley, S.M. , X. Cai, and M.I. Naash, Nonviral optic cistron therapy: appraisal and future waies. Curr Opin Mol Ther, 2008. 10 ( 5 ) : p. 456-63.

7. Cai, X. , S. Conley, and M. Naash, Nanoparticle applications in optic cistron therapy. Vision Res, 2008. 48 ( 3 ) : p. 319-24.

8. Farjo, R. , et al. , Efficient non-viral optic cistron transportation with compacted DNA nanoparticles. PLoS ONE, 2006. 1: p. e38.

9. Cooper, M.J. , Nonviral cistron transportation in the lung: from animate being to human. Molecular therapy, 2007. S15: p. 315.

10. Konstan, M.W. , et al. , Compacted DNA nanoparticles administered to the rhinal mucous membrane of cystic fibrosis topics are safe and demonstrate partial to finish cystic fibrosis transmembrane regulator reconstitution. Hum Gene Ther, 2004. 15 ( 12 ) : p. 1255-69.

11. Ziady, A.G. , et al. , Minimal toxicity of stabilized compacted DNA nanoparticles in the murine lung. Mol Ther, 2003. 8 ( 6 ) : p. 948-56.

12. Yoshioka, M. , et al. , A novel venue, Mody4, distal to D7Mit189 on chromosome 7 determines early-onset NIDDM in nonobese C57BL/6 ( Akita ) mutation mice. Diabetess, 1997. 46 ( 5 ) : p. 887-94.

13. Barber, A.J. , et al. , The Ins2Akita mouse as a theoretical account of early retinal complications in diabetes. Invest Ophthalmol Vis Sci, 2005. 46 ( 6 ) : p. 2210-8.

14. Hernandez, C. and R. Simo, Strategies for barricading angiogenesis in diabetic retinopathy: from basic scientific discipline to clinical pattern. Expert Opin Investig Drugs, 2007. 16 ( 8 ) : p. 1209-26.

15. Lebherz, C. , et al. , Nonhuman archpriest theoretical accounts for diabetic optic neovascularization utilizing AAV2-mediated overexpression of vascular endothelial growing factor. Diabetes, 2005. 54 ( 4 ) : p. 1141-9.

16. Ron, D. , Proteotoxicity in the endoplasmic Reticulum: lessons from the Akita diabetic mouse. J Clin Invest, 2002. 109 ( 4 ) : p. 443-5.

17. Wang, J. , et al. , A mutant in the insulin 2 cistron induces diabetes with terrible pancreatic beta-cell disfunction in the Mody mouse. J Clin Invest, 1999. 103 ( 1 ) : p. 27-37.

18. Gurley, S.B. , et al. , Impact of familial background on kidney disease in diabetic mice. Am J Physiol Renal Physiol, 2006. 290 ( 1 ) : p. F214-22.

19. Schmidt, R.E. , et al. , Neuritic dystrophy and neuronopathy in Akita ( Ins2 ( Akita ) ) diabetic mouse sympathetic ganglia. Exp Neurol, 2009. 216 ( 1 ) : p. 207-18.

20. Cohen, M.P. , et al. , Vitreous fluid of db/db mice exhibits changes in angiogenic and metabolic factors consistent with early diabetic retinopathy. Ophthalmic Res, 2008. 40 ( 1 ) : p. 5-9.

21. Diabetic retinopathy. Diabetes Care, 2000. 23 Suppl 1: p. S73-6.

22. Dawson, D.W. , et al. , Pigment epithelium-derived factor: a powerful inhibitor of angiogenesis. Science, 1999. 285 ( 5425 ) : p. 245-8.

23. Steele, F.R. , et al. , Pigment epithelium-derived factor: neurotrophic activity and designation as a member of the serine peptidase inhibitor cistron household. Proc Natl Acad Sci U S A, 1993. 90 ( 4 ) : p. 1526-30.

24. Becerra, S.P. , et al. , Pigment epithelium-derived factor behaves like a noninhibitory serpin. Neurotrophic activity does non necessitate the serpin reactive cringle. J Biol Chem, 1995. 270 ( 43 ) : p. 25992-9.

25. Bilak, M.M. , et al. , Pigment epithelium-derived factor ( PEDF ) protects centrifugal nerve cells from chronic glutamate-mediated neurodegeneration. J Neuropathol Exp Neurol, 1999. 58 ( 7 ) : p. 719-28.

26. Becerra, S.P. , Focus on Molecules: Pigment epithelium-derived factor ( PEDF ) . Exp Eye Res, 2006. 82 ( 5 ) : p. 739-40.

27. Barnstable, C.J. and J. Tombran-Tink, Neuroprotective and antiangiogenic actions of PEDF in the oculus: molecular marks and curative potency. Prog Retin Eye Res, 2004. 23 ( 5 ) : p. 561-77.

28. Gao, G. , et al. , Unbalanced look of VEGF and PEDF in ischemia-induced retinal neovascularization. FEBS Lett, 2001. 489 ( 2-3 ) : p. 270-6.

29. Garg, S. , et al. , The intercrossed CMV enhancer/chicken beta-actin booster along with woodchuck hepatitis virus posttranscriptional regulative component enhances the protective efficaciousness of DNA vaccinums. J Immunol, 2004. 173 ( 1 ) : p. 550-8.

30. Kosuga, M. , et al. , Strong, long-run transgene look in rat liver utilizing lily-livered beta-actin booster associated with cytomegalovirus immediate-early foil ( CAG booster ) . Cell Transplant, 2000. 9 ( 5 ) : p. 675-80.

31. Davis, P.B. and M.J. Cooper, Vectors for airway cistron bringing. Aaps J, 2007. 9 ( 1 ) : p. E11-7.

32. Cai, X. , et al. , A partial structural and functional deliverance of a retinitis pigmentosa theoretical account with compacted DNA nanoparticles. PLoS ONE, 2009. 4 ( 4 ) : p. e5290.

33. Kreuter, J. , Nanoparticulate systems for encephalon bringing of drugs. Adv Drug Deliv Rev, 2001. 47 ( 1 ) : p. 65-81.

34. Chen, X. , et al. , Cell surface nucleolin serves as receptor for DNA nanoparticles composed of pegylated polylysine and DNA. Mol Ther, 2008. 16 ( 2 ) : p. 333-42.

35. Fink, T.L. , et al. , Plasmid size up to 20 kbp does non restrict effectual in vivo lung cistron transportation utilizing compacted DNA nanoparticles. Gene Ther, 2006. 13 ( 13 ) : p. 1048-51.